thalidomide has been researched along with Precancerous Conditions in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS)." | 9.14 | Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. ( Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA, 2010) |
| "Thalidomide was originally marked as a sedative and anti-emetic, but was withdrawn after severe teratogenic effects had been discovered." | 6.49 | Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. ( Chen, Q; He, M; Huang, H; Jin, X; Lu, S; Mu, D; Wang, L; Xing, X; Zeng, X, 2013) |
| "Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS)." | 5.14 | Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. ( Afable, M; Cuthbertson, D; Ganetsky, R; Ganetzky, R; Latham, D; List, AF; Loughran, TP; Maciejewski, JP; Paquette, R; Paulic, K; Saba, HI; Sekeres, MA, 2010) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| "Thalidomide was originally marked as a sedative and anti-emetic, but was withdrawn after severe teratogenic effects had been discovered." | 2.49 | Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. ( Chen, Q; He, M; Huang, H; Jin, X; Lu, S; Mu, D; Wang, L; Xing, X; Zeng, X, 2013) |
| "Pomalidomide treatment resulted in downregulation of interferon regulatory factor 4, a transcription factor for M2 macrophage polarization." | 1.51 | Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. ( Bastea, LI; Copland, JA; Doeppler, H; Edenfield, B; Fleming, AK; Li, Z; Liou, GY; Pandey, V; Qiu, Y; Storz, P; Tun, HW; von Roemeling, CA, 2019) |
| "Thalidomide has been shown to have anti-angiogenic effects in pre-clinical models as well as a significant antitumor effect in hematologic tumors." | 1.35 | Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis. ( Ge, JP; Yang, Y; Zhou, ZT, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastea, LI | 1 |
| Liou, GY | 1 |
| Pandey, V | 1 |
| Fleming, AK | 1 |
| von Roemeling, CA | 1 |
| Doeppler, H | 1 |
| Li, Z | 1 |
| Qiu, Y | 1 |
| Edenfield, B | 1 |
| Copland, JA | 1 |
| Tun, HW | 1 |
| Storz, P | 1 |
| Molinari, AJ | 2 |
| Thorp, SI | 1 |
| Portu, AM | 1 |
| Saint Martin, G | 1 |
| Pozzi, EC | 2 |
| Heber, EM | 2 |
| Bortolussi, S | 1 |
| Itoiz, ME | 2 |
| Aromando, RF | 2 |
| Monti Hughes, A | 2 |
| Garabalino, MA | 2 |
| Altieri, S | 1 |
| Trivillin, VA | 2 |
| Schwint, AE | 2 |
| Barlogie, B | 1 |
| van Rhee, F | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Yaccoby, S | 1 |
| Pineda-Roman, M | 1 |
| Hollmig, K | 1 |
| Alsayed, Y | 1 |
| Hoering, A | 1 |
| Szymonifka, J | 1 |
| Anaissie, E | 1 |
| Petty, N | 1 |
| Kumar, NS | 1 |
| Srivastava, G | 1 |
| Jenkins, B | 1 |
| Crowley, J | 1 |
| Zeldis, JB | 1 |
| Yang, Y | 1 |
| Ge, JP | 1 |
| Zhou, ZT | 1 |
| Sekeres, MA | 1 |
| List, AF | 1 |
| Cuthbertson, D | 1 |
| Paquette, R | 1 |
| Ganetzky, R | 1 |
| Ganetsky, R | 1 |
| Latham, D | 1 |
| Paulic, K | 1 |
| Afable, M | 1 |
| Saba, HI | 1 |
| Loughran, TP | 1 |
| Maciejewski, JP | 1 |
| Walker, BA | 1 |
| Wardell, CP | 1 |
| Chiecchio, L | 1 |
| Smith, EM | 1 |
| Boyd, KD | 1 |
| Neri, A | 1 |
| Davies, FE | 1 |
| Ross, FM | 1 |
| Morgan, GJ | 1 |
| Nigg, DW | 1 |
| Jin, X | 1 |
| Lu, S | 1 |
| Xing, X | 1 |
| Wang, L | 1 |
| Mu, D | 1 |
| He, M | 1 |
| Huang, H | 1 |
| Zeng, X | 1 |
| Chen, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response | |
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
1 review available for thalidomide and Precancerous Conditions
| Article | Year |
|---|---|
Thalidomide: features and potential significance in oral precancerous conditions and oral cancer.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Feasibility Studies; Humans; Lichen Planus, Oral; Lu | 2013 |
3 trials available for thalidomide and Precancerous Conditions
| Article | Year |
|---|---|
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diphosphonates; Disease Progression; Di | 2008 |
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
Topics: Aged; Azacitidine; Chromosome Aberrations; DNA Methylation; DNA Modification Methylases; DNA Mutatio | 2010 |
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Dexamethasone; D | 2011 |
4 other studies available for thalidomide and Precancerous Conditions
| Article | Year |
|---|---|
Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Topics: Animals; Humans; Immunologic Factors; Interferon Regulatory Factors; Macrophages; Mice; Pancreatic N | 2019 |
Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Boron Compounds; Boron Neutron C | 2015 |
Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Carcino | 2009 |
Blood vessel normalization in the hamster oral cancer model for experimental cancer therapy studies.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Capillary Permeability; Case-Control Studies; Cheek | 2012 |